reports
- Kate Heseltine
Willow Biosciences Inc - Notable progress towards commercialisation
2021 has been a year of notable accomplishments for Willow Biosciences (WLLW). In March, it completed its first commercial-scale production of cannabigerol (CBG). In September, it announced the development of a process for producing high yield cannabigerolic acid (CBGA); both CBG and CBGA are believed to provide health and wellness benefits. WLLW’s processes have the potential to deliver rare cannabinoids at high yields and could give it access to the sizeable cosmetic, consumer and pharmaceutic...
- Kate Heseltine
Willow Biosciences Inc - Notable progress towards commercialisation
2021 has been a year of notable accomplishments for Willow Biosciences (WLLW). In March, it completed its first commercial-scale production of cannabigerol (CBG). In September, it announced the development of a process for producing high yield cannabigerolic acid (CBGA); both CBG and CBGA are believed to provide health and wellness benefits. WLLW’s processes have the potential to deliver rare cannabinoids at high yields and could give it access to the sizeable cosmetic, consumer and pharmaceutic...
Willow Biosciences Announces Increase to Bought Deal Offering from $20...
Willow Biosciences Announces Increase to Bought Deal Offering from $20.0 Million to $25.0 Million NOT FOR DISTRIBUTION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW. VANCOUVER, British Columbia, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW; WLLW.WT; OTCQX: CANSF) is pleased to announce that in connection with its previously announced bought deal offering, Willow and the syndicate of underwriters co-led by Eight Capital and BMO Capital Markets (collectively, the "Under...
Willow Biosciences Announces $20.0 Million Bought Deal Offering
Willow Biosciences Announces $20.0 Million Bought Deal Offering NOT FOR DISTRIBUTION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW. VANCOUVER, British Columbia, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW; OTCQX: CANSF) is pleased to announce that it has entered into an agreement with Eight Capital and BMO Capital Markets, to act as co-lead underwriters, on behalf of a syndicate of underwriters (collectively, the "Underwriters"), pursuant to which the Underwriters ha...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.